The Quantellect read.As of Nov 19, 2026, 5 active firms cover Design Therapeutics Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $21.00 to $26.00, so the covering firms are broadly aligned. The average target of $23.50 sits 148% above the current $9.49. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.35 next quarter toward $-1.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$23.50
+147.6% upside
Average target across 2 active firms as of Nov 19, 2026 vs $9.49 current
Highest Target$26.00
Average Target$23.50
Lowest Target$21.00
Detailed analyst forecasts for DSGN
Showing 1–2 of 2 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate DSGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DSGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.40 – $-0.29 · 5 analysts · +22% YoY
Next period, 5 analysts expect Design Therapeutics Inc to earn $-0.35 a share (range $-0.40 – $-0.29), versus $-0.29 a year earlier. Full-year consensus is $-1.34, growing to $-1.55 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Design Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DSGN.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$20.00+110.7% to target
Overall win rate
52%
+ Follow
#2
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$14.00+47.5% to target
Overall win rate
36%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$20.00+110.7% to target
Overall win rate
30%
+ Follow
#4
KB
Kostas Biliouris
Oppenheimer
Buy
$21.00+121.3% to target
Coverage
—
+ Follow
#5
AV
Adam Vogel
Craig-Hallum
Buy
$22.00+131.8% to target
Coverage
—
+ Follow
DSGN stock forecast FAQ
What is DSGN's average 12-month price target?+
The 2 active firms with a live target average $23.50 for Design Therapeutics Inc over the next 12 months, ranging from a $26.00 high to a $21.00 low, as of Nov 19, 2026.
Is DSGN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DSGN?+
The Street-high target is $26.00 (Wells Fargo), and the Street-low is $21.00 (Oppenheimer). The average of all 2 active-firm targets is $23.50.
How many active Wall Street firms cover DSGN?+
5 active firms have a recognized rating on Design Therapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DSGN?+
Among analysts who currently cover DSGN, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $20.00 target.
What is Design Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.40 – $-0.29) across 5 analysts. Full-year EPS is projected at $-1.34, rising to $-1.55 the following year.
How much revenue is Design Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading DSGN lately?+
As of Nov 19, 2026, 5 of 5 active firms rate DSGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DSGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.